David L. Kok

Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy

David L. Kok, Suki Gill, Mathias Bressel et al. · Radiotherapy and Oncology · 2013 · 63 citations

Medicine, Oncology, Urology +16

Teaching a fishbowl tutorial: sink or swim?

Ruth Sutherland, David L. Kok, Margo E Collins · The Clinical Teacher · 2012 · 30 citations

Education, Medical Education, Teaching +9

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Peter K. H. Lau, Breon Feran, Lorey Smith et al. · Journal for ImmunoTherapy of Cancer · 2021 · 29 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).

Maria Gonzalez, Angela Hong, Matteo S. Carlino et al. · Journal of Clinical Oncology · 2019 · 24 citations

Medicine, Oncology, Pharmacotherapy +17

URBAN–RURAL DIFFERENCES IN THE MANAGEMENT OF SCREEN‐DETECTED INVASIVE BREAST CANCER AND DUCTAL CARCINOMA <i>IN SITU</i> IN VICTORIA

David L. Kok, Jiun‐Horng Chang, Bircan Erbas et al. · ANZ Journal of Surgery · 2006 · 21 citations

Medicine, Oncology, Surgery +16